Anastasis Biotec

Anastasis Biotec is a private, pre-clinical stage biotechnology company developing novel, targeted human protein and peptide therapeutics for oncology and infectious diseases. The company's proprietary Antennapedia Transporter Protein (ANTP) platform enables therapeutic proteins and peptides to penetrate target tissues, cross the blood-brain barrier, and enter cells to inhibit intracellular disease-driving pathways. Anastasis Biotec's lead pipeline candidates include S4 (Syntana-4), a cell-penetrating Notch pathway inhibitor being developed for prostate and breast cancer stem cells, and AB1, a therapeutic fusion protein designed to deliver the p21 tumor suppressor to selectively eliminate p53-mutated cancer cells. Additionally, the company is developing a therapeutic targeting the Mpro enzyme for the treatment of COVID-19.